Transmembrane helix seven residues of G protein-coupled receptors (GPCRs) couple agonist binding to a conserved receptor activation mechanism. Amino-terminal residues of the GnRH peptide determine agonist activity. We investigated GnRH interactions with the His 
Introduction
Gonadotropin-releasing hormone (GnRH) is the central regulator of reproductive function. It is a decapeptide (pGlu 1 -His 2 -Trp 3 -Ser 4 -Tyr 5 -Gly 6 -Leu 7 -Arg 8 -Pro 9 -Gly 10 -NH 2 )
that binds to receptors in the pituitary and stimulates synthesis and secretion of luteinizing hormone and follicle stimulating hormone. These gonadotropic hormones, in turn, regulate gametogenesis and gonadal sex hormone production. The GnRH receptor is a rhodopsin-like, class A, G protein-coupled receptor (GPCR) that transduces the GnRH binding signal across the cell membrane via changes in receptor protein conformation that activate intracellular G proteins and inositol phosphate (IP) signaling Naor and Huhtaniemi, 2013; Pincas et al., 2014; Sefideh et al., 2014; Thompson and Kaiser, 2014) .
GnRH analogs have been used for treatment of a range of reproductive hormonedependent disorders, including various forms of infertility as well as hypertrophy and cancers of reproductive tissues (Betz et al., 2008; Kim et al., 2009; Labrie et al., 2005; Millar et al., 2004; Samant et al., 2005; Schally et al., 1990) . Many peptide ligands, including chemokines and endogenous opioids, interact with their receptors via two sites, one that determines binding affinity and a second site that induces receptor activation (Choi et al., 2012; Filizola and Devi, 2013; Flanagan, 2014; Granier et al., 2012; Pease and Horuk, 2012; Portoghese, 1992 ). GnRH structure-activity studies have shown that amino acids at both the amino-and carboxy-termini of the peptide are required for high-affinity binding to the GnRH receptor, whereas the amino-terminal residues determine agonist activity and receptor activation (Karten and Rivier, 1986; Millar et al., 2004; Sealfon et al., 1997) .
In the absence of crystal structures of the GnRH receptor, computational models have been used to infer ligand binding interactions (Chauvin et al., 2000; Hovelmann et al., 2002; Li et al., 2005; Soderhall et al., 2005) . However, only a few of the proposed contacts have been validated with appropriate ligand modifications Sealfon et al., 1997) . The Arg 1.35(38) and Asn 2.65(102) residues (Ballesteros and Weinstein receptor residue numbering system, see under "Materials and Methods" for explanation) at the extracellular ends of the first and second transmembrane helices (TM) of the GnRH receptor contribute to recognition of the carboxy-terminal Gly 10 NH 2 moiety of GnRH (Davidson et al., 1996; Stewart et al., 2008) , an acidic residue at the extracellular end of TM7 recognizes the basic Arg 8 residue, which is important for high affinity binding of GnRH (Flanagan et al., 1994; Fromme et al., 2001 ) and the Tyr 6.58(290) side chain determines recognition of Tyr 5 of GnRH (Coetsee et al., 2008) . Receptor interactions of the amino-terminal residues of GnRH that are important for agonist activity are less well-defined. The His 2 side chain forms a hydrogen bond with Asp 2. 61(98) , which is thought to also form an intramolecular salt bridge with Lys 3.32(121) that is important for receptor transition between inactive and activated receptor conformations (Flanagan et al., 2000; Zhou et al., 1995) . Other amino-terminal functional groups of GnRH may also induce changes in intramolecular receptor bonds that result in receptor activation. The Trp 3 residue of GnRH has been proposed to interact with receptor residues in the TM6 and second extracellular loop, but some of these are controversial (Chauvin et al., 2000; Coetsee et al., 2006; Forfar and Lu, 2011) .
The presence and orientation of an acidic residue (Glu 7.32(301) in rodents or Asp 7.32(302) in other mammals) at the extracellular end of TM7 of the GnRH receptor is important for binding both GnRH analogs and non-peptide antagonists (Betz et al., 2006b; Betz et al., 2008; Flanagan et al., 1994; Fromme et al., 2004; Fromme et al., 2001; Wang et al., 2004) . 7.36(306) residue, one helical turn further along TM7, to Ala, Glu or Lys decreased receptor affinity for GnRH and antagonist and it was suggested that the His 7.36(306) side chain might have a function similar to that of Asp 7.32(302) (Betz et al., 2006b) . It was subsequently shown that the Asp 7.32(302) and His 7.36(306) side chains form hydrogen bonds with a small molecule antagonist (Betz et al., 2006a) , but the roles of His 7.36(306) in GnRH binding and receptor signaling were not explored. Although the ligand binding pocket of each GPCR is specific for its cognate ligand, receptor functional groups that interact with agonist ligands are structurally coupled to a network of highly conserved amino acids in the transmembrane domain that constitute a conserved structural mechanism that converts the receptor to the active GPCR conformation (Deupi and Standfuss, 2011) . The few published GPCR crystal structures that include peptide ligands show direct (Egloff et al., 2014; White et al., 2012) or water-mediated (Wu et al., 2010) peptide interactions with residues in TM7, including the residue in position 7.36 (Venkatakrishnan et al., 2013) . The equivalent residues, Asp 7.39(288) of the CXCR4 chemokine receptor and Glu 7.39(283) of the CCR5 chemokine receptor, constitute part of the "site two" agonist interaction site that activates these peptide-binding GPCRs (Tan et al., 2013; Wu et al., 2010) . More broadly, the position 7.39 residue is considered to be a "consensus" residue that interacts with ligands in many GPCRs and connects to the conserved transmembrane domain network (Venkatakrishnan et al., 2013) . Thus, agonistinduced perturbation of the extracellular end of TM7 is part of the GPCR activation process that results in the large rearrangements of the cytosolic receptor surface that activate intracellular signaling molecules (Venkatakrishnan et al., 2013) .
Mutation of the His
His residues are important in the active sites of many enzymes (Meurisse et al., 2003; Vila et al., 2011) . Because the imidazole side chain is reversibly protonated and deprotonated at physiological pH and the un-protonated form occurs as two different tautomeric structures (Heyda et al., 2010; Meurisse et al., 2003; Mikulski et al., 2011; Vila et al., 2011; Walters and Allerhand, 1980; Williams et al., 2003) 
Materials and Methods

GnRH Analogs
Mammalian GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH 2 ) and GnRH II 
Amino acid residue numbering system
The Ballesteros and Weinstein consensus numbering system (Ballesteros and Weinstein, 1995 ) is used to identify receptor amino acids and to facilitate comparison with other rhodopsin-type GPCRs. The most conserved residue of each TM is designated .50 and residues are identified by the TM number and a number that indicates its position relative to the most conserved residue, followed by the receptor sequence number in parenthesis. Thus, , by 14 residues. The equivalent residue of the human GnRH receptor is designated His 7.36(306) , because of an additional residue in extracellular loop two. The mouse GnRH receptor was used in this study, because it is better expressed than the human receptor (Arora et al., 1999) . The better expression facilitates analysis of mutations that decrease receptor expression or function.
Site-directed mutagenesis
Polymerase chain reaction (PCR) based site-directed mutagenesis was used to substitute England Biolabs, Inc, Beverly, USA) and then used to transform DH10B E. Coli, which were cultured overnight on ampicillin agar plates. DNA extracted from colonies was screened for the presence of mutations by digestion with silent mutation-specific restriction enzymes.
Mutant receptor genes were sequenced to confirm the mutation and ensure absence of PCRgenerated errors and subcloned into the Eco RI and Xho I sites of the pcDNAI/Amp vector.
Cell culture and transfection
COS-1 cells (American Type Culture Collection) were maintained in antibiotic-free Dulbecco's modified eagle's medium (DMEM) (Gibco, Paisley, Scotland) containing 10 % fetal calf serum (FCS) (Delta Bioproducts, Kempton Park, South Africa) at 37C in a 10 % CO 2 humidified incubator. COS-1 cells were transiently transfected using the DEAE-Dextran method, as described previously . Cells (3 x10 6 per 10cm dish) were incubated (4 hrs, 37° C) with plasmid DNA (15g) and DEAE-Dextran (0.3 mg/ml) in serum-free DMEM (4 ml), incubated in chloroquine (200 M in DMEM, 50 min) then treated with dimethylsulfoxide (10 % in DMEM, 2 min) and cultured overnight in DMEM with 10 % FCS and antibiotics (streptomycin sulphate, 2mg/ml and sodium benzylpenicilin, 4000U/ml). Cells were plated in 12-well plates the day after transfection for IP production and whole-cell binding assays. Aldrich, South Africa) as previously described and radioactivity was counted in a beta scintillation counter.
IP production assays
Ligand Binding Assays
[His 5 ,D-Tyr 6 ]-GnRH was radio-iodinated as previously described (Flanagan et al., 1998) , purified on a QAE-Sephadex column as previously described , aliquoted and stored (-70° C). unlabeled GnRH agonists (final volume, 0.5 ml). Cells were washed with phosphate-buffered saline (3 x 1ml) before addition of NaOH (0.1 M, 1 ml/well). Radioactivity in the NaOH solution was counted in a gamma counter.
Membrane binding assays were performed as previously described (Flanagan et al., 1998; Hulme and Birdsall, 1992) . The incubation was terminated by dilution with polyethylenimine (PEI, 0.01 %, 3ml) and filtration (Brandel Cell Harvester) through glass fiber filters (GF/C, Whatman) pre-soaked for 30 minutes in PEI (1 %). Filters were washed twice with PEI (0.01 %, 3 ml) and retained radioactivity was counted. Antagonist 27 (1 M) was used to estimate non-specific binding.
Data Analysis
IP production and whole-cell binding assays were performed at least four times in Tables 1 and 3, to facilitate comparison of mutant receptor signaling efficiency (Ballesteros et al., 1998 (Motulsky, 1999) .
Molecular Modeling
A homology model for GnRH and mouse GnRH receptor interaction was built with the homology modeling program MODELLER 9v12 (Sali and Blundell, 1993) and was based on the high resolution crystal structures of agonist-bound rat neurotensin receptor type 1 (rNTR1, Protein Data Bank code: 4GRV) (White et al., 2012) , which is also a peptide Structures for the mutants were generated by homology modeling using the model structure of the wild type receptor and GnRH complex as the template.
Results
IP production
To identify which mutations affected GnRH receptor function, mutant receptors were screened for their ability to mediate GnRH-stimulated cellular signaling. Trp mutant exhibited low GnRH potency and a low E max (Fig. 1, Table 1 ).
Ligand binding
Whole-cell ligand binding assays were used initially to investigate whether decreased IP production mediated by mutant GnRH receptors resulted from decreased cell surface receptor expression, ligand affinity or coupling efficiency. Homologous competition assays were used to assess receptor expression levels, whereas heterologous GnRH competition binding was used to assess whether decreased ligand binding affinity might account for decreased potencies in IP assays. Phe mutant GnRH receptor showed a statistically significant decrease in affinity for GnRH in the whole-cell binding assay ( Table   2 ).
As the whole-cell binding assays showed evidence of ligand depletion for some receptors (B 0 > 10 % of total radioactivity) (Hulme and Birdsall, 1992) 
Binding affinities of GnRH analogs at wild type and mutant GnRH receptors
The 
[2-Nal 3 ]-GnRH stimulation of IP production at wild type and mutant GnRH receptors
The amino-terminal residues of GnRH, including Trp 3 , are important for agonist activity of the peptide at the GnRH receptor, in contrast to the carboxy terminal residues, which are important primarily for high binding affinity Asn mutant receptor (Fig. 4, Figure 5C ), whereas substitutions with non-polar Ala ( Figure 5D) Previous studies have shown that mutations of residues at the extracellular end of TM7 of the GnRH receptor disrupt GnRH binding and the resulting models of receptor-ligand binding have included direct interactions of these residues with specific residues of GnRH or GnRH peptide analogs (Betz et al., 2006b; Chauvin et al., 2001; Coetsee et al., 2008; Flanagan et al., 1994; Fromme et al., 2004; Fromme et al., 2001; Hovelmann et al., 2002; Millar et al., 2004; Wang et al., 2004) . Mutations of His 7.36(306) of the human GnRH receptor had disruptive effects on binding of GnRH and a non-peptide antagonist that were similar to the effects of mutating Asp 7.32(302) (Betz et al., 2006b ). Subsequent structure-activity relationship studies concluded that the Asp 7.32(302) and His 7.36(306) side chains form hydrogen bonds with adjacent functional groups of the antagonist (Betz et al., 2006a) , but the roles of the His 7.36 side chain in binding GnRH peptides and in receptor activation were not reported. The imidazole side chain of His can form π-stacking interactions with other aromatic side chains (Meurisse et al., 2003; Mikulski et al., 2011; Wang et al., 2006; Williams et al., 2003) . It is also reversibly protonated at physiological pH (Heyda et al., 2010; Vila et al., 2011) and the neutral form occurs in both of its tautomeric structures, which have a hydrogen atom attached to either the δ1-or the ε2-nitrogen atom. Hence, the His side chain can act as a proton shuttle, a donor and an acceptor of hydrogen bonds and it can rotate (Heyda et al., 2010; Meurisse et al., 2003; Mikulski et al., 2011; Vila et al., 2011; Walters and Allerhand, 1980; Williams et al., 2003 (Lebon et al., 2012) .
Recent GPCR crystal structures have allowed identification of a conserved network of non-covalent interhelical interactions that is important for receptor protein structure and function and includes six residues in TM7 (Venkatakrishnan et al., 2013) . Small molecule ligands, including retinal, monoamines and opioids, interact with a consensus ligand binding pocket made up of topologically equivalent residues in TM3, TM6 and TM7 (Venkatakrishnan et al., 2013) . The residue in position 7.39 forms part of both the consensus ligand binding pocket and the interhelical network and thus potentially couples binding of diverse ligands with the conserved receptor structure (Venkatakrishnan et al., 2013) . Crystal agonists, agonist interactions with residues in TM3, TM5, TM6 and TM7 cause small (in the cases of rhodopsin, β adrenergic and adenosine receptors) or large (in the cases of muscarinic and purinergic receptors) changes in the ligand binding pocket that draw the extracellular ends of these helices together and contract the pockets of receptors that bind dissociable ligands, but widen the retinal pocket in rhodopsin (Deupi et al., 2012a; Deupi et al., 2012b; Katritch and Abagyan, 2011; Kruse et al., 2013; Lebon et al., 2012; Rasmussen et al., 2011a; Ring et al., 2013; Venkatakrishnan et al., 2013; Xu et al., 2011; Zhang et al., 2014a; Zhang et al., 2014b with residues in the cytosolic ends of TM3, TM5 and TM6 to stabilize the active receptor conformation (Deupi et al., 2012a; Deupi and Standfuss, 2011; Deupi et al., 2012b; Standfuss et al., 2011; Trzaskowski et al., 2012; Venkatakrishnan et al., 2013) . It is notable that the key receptor residues that mediate agonist activity differ. In the β 2 adrenergic receptor the TM5 Ser 5.42 and Ser 5.46 residues are key for agonist activity, whereas the TM7 residues, Ser 7.42 and His 7.43 , are key for activation of the A 2A adenosine receptor (Katritch and Abagyan, 2011; Lebon et al., 2012; Xu et al., 2011) . Similarly, agonist ligands interact directly with Trp 6.48 and Tyr 6.51 (in the CWxPY motif) of rhodopsin and the A 2A adenosine
receptor, but not the β 2 adrenergic receptor (Deupi and Standfuss, 2011; Katritch et al., 2013) .
These results show that agonists interact with different combinations of residues to trigger receptor activation. Although small ligands bind in the transmembrane domain and interact with some of the highly conserved residues that regulate receptor activation, much biochemical evidence suggests that larger, peptide ligands bind to the extracellular GPCR surface (Ji et al., 1998 (Egloff et al., 2014; Trzaskowski et al., 2012; White et al., 2012; Wu et al., 2010) . This suggests that intramolecular interactions may couple extracellular agonist peptide binding pockets to the conserved transmembrane interaction network that mediates receptor activation.
Agonist peptides form hydrogen bond interactions with Tyr 7.30(347) of the NTR1 neurotensin receptor (Egloff et al., 2014; White et al., 2012) and van der Waals interactions with other residues in TM7 (White et al., 2012) . The CVX15 antagonist peptide makes a water-mediated contact with Asp 7.39(288) , which is part of the activation site of the CXCR4 chemokine receptor (Wu et al., 2010 (Filizola and Devi, 2013; Granier et al., 2012) . Since these TM7
residues are also important for agonist activity, they likely participate in coupling agonist binding to the conserved transmembrane domain scaffold (Venkatakrishnan et al., 2013 ) and the molecular pathways that mediate receptor activation (Deupi et al., 2012b) . 7.36(305) (Fersht et al., 1985) . On the other hand, three substitutions of (Coetsee et al., 2008; Flanagan et al., 2000; Forfar and Lu, 2011; Soderhall et al., 2005) .
A polar functional group of the His
Based on a small number of mutations, many GnRH-receptor models have included contacts of Trp 3 of GnRH agonists with the Trp 6.48 residue (of the CWxPY motif) (Betz et al., 2006b; Chauvin et al., 2000; Chauvin et al., 2001; Hovelmann et al., 2002; Millar et al., 2004; Soderhall et al., 2005 ]-GnRH. Although a π-stacking interaction was proposed (Forfar and Lu, 2011) , loss of a weak aromatic interaction is unlikely to account for the large decrease in GnRH binding affinity at the Phe 4.64(178) Ala mutant receptor (Fersht et al., 1985) . Indeed disruption of a crystallographically-confirmed van der Waals interaction using a similar mutation decreases affinity of the neurotensin receptor, NTSR1, five to ten-fold (White et al., 2012) . The results suggest rather, that the Phe 4.64(178) Ala mutation disrupts the protein structure (Fersht, 1987) and decreases GnRH affinity via indirect effects that distort the ligand binding surface. (Jacobson and Costanzi, 2012; Katritch et al., 2013; Rasmussen et al., 2011b; Samama et al., 1993; Venkatakrishnan et al., 2013) . It is well-established that modifications of amino terminal residues decrease efficacy of GnRH peptides, converting them to antagonists (Sealfon et al., 1997) . As we have previously demonstrated significant receptor reserve in the current GnRH receptor expression system (Zhou et al., 1995) 
